Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Thoracic 3Head & Neck 3Tumor-Agnostic 2Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 765Gemcitabine 651Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 441Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 218pembrolizumab 206Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 181Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × adavosertib × Gastrointestinal × Clear all
NCT05212025 2022-06-14

Adavosertib and Gemcitabine in Advanced Pancreatic

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT02906059 2020-10-12

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

NYU Langone Health

Phase 1 Completed
7 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡